Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Author:Hess, Gregory P. MD, MSc; Natarajan, Pradeep MD, MMSc; Faridi, Kamil F. MD; Fievitz, Anna BS; Valsdottir, Linda MS; Yeh, Robert W. MD, MSc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου